Huleatt, Paul B <br/><br/>
Novel arylalkenylpropargylamines as neuroprotective, potent, and selective monoamine oxidase B inhibitors for the treatment of Parkinson's disease.  [electronic resource] 

 -  Journal of medicinal chemistry  Feb 2015 
 - 1400-19 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1520-4804 
<br/><br/><label>Standard No.: </label>10.1021/jm501722s  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Cell Survival--drug effects<br/>Cells, Cultured<br/>Dose-Response Relationship, Drug<br/>Humans<br/>Mice<br/>Molecular Structure<br/>Monoamine Oxidase--metabolism<br/>Monoamine Oxidase Inhibitors--chemical synthesis<br/>Neuroprotective Agents--chemical synthesis<br/>PC12 Cells<br/>Pargyline--analogs & derivatives<br/>Parkinson Disease--drug therapy<br/>Propylamines--chemical synthesis<br/>Rats<br/>Structure-Activity Relationship